Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

2209 ARTÍCULOS , VIENDO DEL 2011 AL 2025

Early axonal degeneration linked to clinical decline in Alzheimer's disease progression revealed with diffusion MRI

Gong Z, Laporte JP, Guo AY, Bilgel M, Bae J, Fox NY, de Rouen A, Zhang N, Taranath A, de Cabo R, Egan JM, Ferrucci L, Bouhrara M; Alzheimer’s Disease Neuroimaging Initiative.

J Clin Invest. 2025 Nov 27;136(3):e196638. doi: 10.1172/JCI196638. eCollection 2026 Feb 2.

Antiamyloid Therapy and Cerebral Blood Flow Changes on MRI: A Potential Longitudinal Biomarker of Treatment Response?

Ricaurte-Fajardo A, Ivanidze J, Zhang D, Mahmud M, Yasen W, Ravdin L, Pahlajani S, Leon M, Nordvig AS, Chiang GC.

AJNR Am J Neuroradiol. 2025 Jul 1;46(7):1439-1445. doi: 10.3174/ajnr.A8654.

The Eye as a Window to Brain Health: Can Retinal Imaging and AI Modeling Predict Alzheimer's Disease?

Awodiya E.

Brain Behav. 2025 Oct;15(10):e70890. doi: 10.1002/brb3.70890.

Cerebellar atrophy in biologically confirmed Alzheimer's disease: Associations with amyloidopathy measured by cerebrospinal fluid biomarkers

Munoz-Musat E, Le Prince G, Delmaire C, Paquet C.

J Alzheimers Dis. 2025 Dec;108(3):1204-1211. doi: 10.1177/13872877251386085. Epub 2025 Oct 17.

Identifying a combination of biomarkers to predict treatment response to nabilone for agitation in Alzheimer's disease - an exploratory post hoc analysis

Wang HJ, Ruthirakuhan M, Andreazza AC, Beroncal EL, Black SE, Gallagher D, Herrmann N, Kiss A, Verhoeff NPLG, Lanctôt KL.

Neurodegener Dis Manag. 2026 Apr-Jun;16(3):263-272. doi: 10.1080/17582024.2025.2587549. Epub 2025 Nov 11.

A neuropathology case report of a woman with Down syndrome who remained cognitively stable: Implications for resilience to neuropathology

Liou JJ, Lou J, Flores-Aguilar L, Nakagiri J, Yong W, Hom CL, Doran EW, Totoiu MO, Lott I, Mapstone M, Keator DB, Brickman AM, Wright ST, Nelson B, Lai F, Xicota L, Dang LT, Li J, Santini T, Mettenburg JM, Ikonomovic MD, Kofler J, Ibrahim T, Head E; Alzheimer Biomarker Consortium ‐ Down Syndrome.

Alzheimers Dement. 2025 Feb;21(2):e14479. doi: 10.1002/alz.14479. Epub 2025 Jan 27.

Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional Trials

Abushakra S, Doraiswamy PM, Hey JA, Tosun D, Barkhof F, Barakos J, Petrella J, Kesslak JP, Power A, Sabbagh M, Porsteinsson A, Cohen S, Gauthier S, Ritchie C, Watson D, McSweeney E, Boada M, Liang E, Bracoud L, McLaine R, Flint S, Schaefer JF, Yu J, Bray M, Hendrix S, Dickson S, Durrant A, Albayrak A, Tolar M.

CNS Drugs. 2026 Feb;40(2):199-214. doi: 10.1007/s40263-025-01251-y. Epub 2025 Dec 1.

PDE5 Inhibitors as Modulators of Alzheimer's-Associated Inflammation and Oxidative Stress: A Meta-Analytical Assessment of Preclinical Studies

Uppuluri CT, Prasad YSKV, Asadi K, Kumari TP, Pelluri R, Chakravarthi G, Nalluri BN, Gurram PC.

Mol Neurobiol. 2025 Dec 23;63(1):322. doi: 10.1007/s12035-025-05635-5.

Exploring the gut-brain-microbiome axis in Alzheimer's disease: Integrating metagenomics, metabolomics, and artificial intelligence for next-generation biomarker discovery

Oso TA, Ahmed MM, Okesanya OJ, Adebayo UO, Obadeyi KB, Othman ZK, Lucero-Prisno DE 3rd.

J Alzheimers Dis. 2026 Feb;109(4):1542-1557. doi: 10.1177/13872877251407700. Epub 2025 Dec 29.

Exploring precision medicine by utilizing individual genetic information for the management of Alzheimer's disease

Kanda A, Rani A, Mazumder A.

Pharmacogenomics. 2025 Jul-Aug;26(10-12):455-474. doi: 10.1080/14622416.2025.2560296. Epub 2025 Sep 15.

Understanding Cerebral Blood Flow Dynamics for Alzheimer's Disease Prevention Through Acute Exercise (flADex): Protocol for a Randomized Crossover Trial

Martín-Fuentes I, Fernandez-Gamez B, Vidal-Almela S, Caro-Rus A, Solis-Urra P, Sánchez-Aranda L, Fernández-Ortega J, Sanchez-Martinez J, Coca-Pulido A, Olvera-Rojas M, Barranco-Moreno EJ, Marin-Alvarez JD, Bakker EA, Toval A, Bellón D, Sclafani A, Karikari TK, Erickson KI, Gómez-Río M, Ortega FB, Esteban-Cornejo I.

Brain Behav. 2025 Nov;15(11):e70636. doi: 10.1002/brb3.70636.

Influence of age and sex on presymptomatic phases of neurodegenerative diseases: Focus on multiple sclerosis and Alzheimer's disease

Zeydan B, Kantarci K.

Rev Neurol (Paris). 2025 Nov;181(9):829-838. doi: 10.1016/j.neurol.2025.06.015. Epub 2025 Aug 6.

Comparison of CSF neurofilament light chain and total tau as neurodegeneration markers: Associations with synaptic markers and cognitive outcomes

Richter G, Kirsebom BE, Jarholm JA, Pålhaugen L, Gísladóttir B, Aarsland D, Grøntvedt GR, Skogseth RE, Waterloo K, Fladby T, Nordengen K.

Neurobiol Aging. 2025 Nov;155:13-23. doi: 10.1016/j.neurobiolaging.2025.07.005. Epub 2025 Jul 10.

Alzheimer's disease diagnosis and treatment: From pathophysiological insights to therapeutic advances in the era of precision neurology (2025 review)

Kim M, Kwon H, Sohn S, Lee WJ, Cho K, Kim GW.

J Alzheimers Dis. 2026 Jan;109(1):17-33. doi: 10.1177/13872877251391820. Epub 2025 Oct 29.

The neuroinflammatory role of microRNAs in Alzheimer's disease: pathological insights to therapeutic potential

Liu W, Rao X, Sun W, Chen X, Yu L, Zhang J, Chen J, Zheng X.

Mol Cell Biochem. 2025 May;480(5):2689-2706. doi: 10.1007/s11010-024-05164-0. Epub 2024 Nov 20.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias